JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karimi-Busheri, F.
Right arrow Articles by Weinfeld, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karimi-Busheri, F.
Right arrow Articles by Weinfeld, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 34, 24187-24194, August 20, 1999


Molecular Characterization of a Human DNA Kinase*

Feridoun Karimi-BusheriDagger , Graham Daly§, Peter Robins§, Benito Canas, Darryl J. C. Pappin, John Sgouros, Gerald G. Millerparallel , Habib Fakhrai**, Elizabeth M. DavisDagger Dagger , Michelle M. Le BeauDagger Dagger , and Michael WeinfeldDagger §§

From Dagger  Experimental Oncology, Cross Cancer Institute, Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada, the § Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Hertfordshire EN6 3LD, United Kingdom, the  Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom, the parallel  Noujaim Institute for Pharmaceutical Oncology Research, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2N8, Canada, ** Advanced Biotherapies, San Diego, California 92121, and the Dagger Dagger  Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human polydeoxyribonucleotide kinase is an enzyme that has the capacity to phosphorylate DNA at 5'-hydroxyl termini and dephosphorylate 3'-phosphate termini and, therefore, can be considered a putative DNA repair enzyme. The enzyme was purified from HeLa cells. Amino acid sequence was obtained for several tryptic fragments by mass spectrometry. The sequences were matched through the dbEST data base with an incomplete human cDNA clone, which was used as a probe to retrieve the 5'-end of the cDNA sequence from a separate cDNA library. The complete cDNA, which codes for a 521-amino acid protein (57.1 kDa), was expressed in Escherichia coli, and the recombinant protein was shown to possess the kinase and phosphatase activities. Comparison with other sequenced proteins identified a P-loop motif, indicative of an ATP-binding domain, and a second motif associated with several different phosphatases. There is reasonable sequence similarity to putative open reading frames in the genomes of Caenorhabditis elegans and Schizosaccharomyces pombe, but similarity to bacteriophage T4 polynucleotide kinase is limited to the kinase and phosphatase domains noted above. Northern hybridization revealed a major transcript of approximately 2.3 kilobases and a minor transcript of approximately 7 kilobases. Pancreas, heart, and kidney appear to have higher levels of mRNA than brain, lung, or liver. Confocal microscopy of human A549 cells indicated that the kinase resides predominantly in the nucleus. The gene encoding the enzyme was mapped to chromosome band 19q13.4.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transient DNA strand breaks and short gaps are frequently observed in cellular DNA. Many arise during regular cellular activity such as DNA replication, recombination, or differentiation. Others occur as a consequence of exposure to endogenous or exogenous DNA damaging agents. Repair of these strand interruptions is usually mediated by DNA ligases and polymerases. Both of these classes of enzymes require 3'-hydroxyl DNA termini, and the DNA ligases also require 5'-phosphate termini. However, the termini generated by nucleases, such as DNase II, and many produced by ionizing radiation bear 3'-phosphate and 5'-hydroxyl groups (1-4), and therefore must be processed before they can be acted upon by DNA ligases or polymerases.

One enzyme that possesses the capacity to both phosphorylate 5'-hydroxyl termini and dephosphorylate 3'-phosphate termini is polynucleotide kinase (PNK).1 The PNK from T4 phage has found widespread application in molecular biology, especially for radiolabeling DNA and oligonucleotides (5). It can act on DNA and RNA and even phosphorylate nucleoside 3'-monophosphates. However, the main cellular function of the T4 enzyme is not to repair DNA, but rather to counter the action of a phage endoribonuclease that cleaves tRNA (6). Eukaryotic PNKs fall into two categories depending on whether their preferred substrate is DNA or RNA (7). While both can phosphorylate 5'-termini, only the former have an associated 3'-phosphatase activity (8-12).

Mammalian DNA kinases have been purified from a variety of sources including rat liver and testes and calf thymus (8-19). The isolated enzymes share similar properties with regard to the kinase activity including an acidic pH (5.5-6.0) optimum (8-18), and the minimum size of oligonucleotide that can be phosphorylated is in the range of 8-12 nucleotides (11, 15). The only significant discrepancy has been the molecular mass assigned to the polypeptides. Earlier reports regarding the PNK purified from rat organs indicated that the protein may be an 80-kDa homodimer composed of 40-kDa polypeptides (9, 10, 18), but PNK activity in tissue extracts detected on activity gels migrated as a 60-kDa polypeptide (20). Estimates for the size of calf thymus PNK have ranged from 56 to 70 kDa (16, 17). We and others have recently purified the DNA kinases from calf thymus and rat liver to near homogeneity, making use of a broad spectrum of proteolysis inhibitors (11, 12). The major protein band migrated as a 60-kDa peptide on polyacrylamide gels, but a minor band was observed at 40 kDa in the rat liver preparation.

At present, the cellular function of mammalian DNA kinases has not been elucidated. Clearly, one possibility is participation in the repair of strand breaks induced by DNA damaging agents, such as ionizing radiation or topoisomerase inhibitors (21, 22). We have shown that, unlike T4 phage PNK, calf thymus PNK is able to efficiently phosphorylate the 5'-OH terminus at a nick and a one-nucleotide gap in a double-stranded DNA substrate (11). Furthermore, an in vitro system consisting of purified mammalian PNK, DNA polymerase beta , and DNA ligase I was able to effect the complete repair of nicks and short gaps bounded by 3'-phosphate and 5'-OH termini (21). Alternatively, PNK could participate in a more regular function. For example, it has been observed that a proportion of Okazaki fragments have 5'-OH termini (23), which would have to be phosphorylated prior to ligation. As part of our ongoing study to address the question of the role of eukaryotic PNKs, this paper describes the molecular cloning, sequencing, cellular localization, and chromosomal mapping of human PNK.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphorylation Assay-- The DNA substrate containing 5'-OH termini was prepared by digestion of calf thymus DNA with micrococcal nuclease as described by Richardson (24). Each 5'-phosphorylation reaction mixture (20 µl), containing 10 µg of DNA substrate, 3 µCi of [gamma -32P]ATP (3000 Ci/mmol, Amersham Pharmacia Biotech), 500 nM unlabeled ATP, 80 mM succinic acid, pH 5.5, 10 mM MgCl2, 1 mM dithiothreitol, 1 mM EGTA, 2 µg of bovine serum albumin, and protein fraction (typically 4 µl), was incubated for 20 min at 37 °C. The reaction was stopped and the DNA precipitated by addition of 200 µl of 20% trichloroacetic acid and 100 µl of 250 µM sodium pyrophosphate containing 50 µg of bovine serum albumin. Following centrifugation at 10,000 × g for 10 min, the pellets were resuspended in 80 µl of 0.1 M NaOH and reprecipitated by addition of 400 µl of 10% trichloroacetic acid. This wash step was repeated once more before the radioactivity of the pellet was determined. As a control for kinase specificity (i.e. DNA versus protein), parallel reactions were carried out in the absence of the DNA substrate.

3'-Phosphatase Assay-- The 3'-dephosphorylation of a 21-mer oligonucleotide (p21p) catalyzed by recombinant human PNK in Escherichia coli cell extracts was assayed by gel electrophoresis as described previously (21).

Partial Purification of Polydeoxyribonucleotide Kinase from HeLa Cells-- A pellet of frozen HeLa S3 cells (3 × 1010, approximately 50 ml packed cell volumes) was thawed in 200 ml of hypotonic buffer (10 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 5 mM dithiothreitol, and 0.5 mM EDTA) containing a mixture of protease inhibitors (25 µg/ml Nepsilon -p-tosyl-L-lysine chloromethyl ketone, 5 µg/ml chymotrypsin, 1 µg/ml aprotinin, 0.5 µg/ml leupeptin, 0.5 µg/ml pepstatin, and 1 mM alpha -toluenesulfonyl fluoride) and held for 20 min at 0 °C before disruption in a Dounce glass homogenizer (15 strokes). Nuclei were collected by low speed centrifugation, and a protein extract was prepared in the presence of 0.3 M KCl as described previously (25). Sequential chromatography of the extract on a phosphocellulose P11 column (Whatman, Clifton, NJ) and an Ultrogel AcA34 gel filtration column (Sepracor/IBF, Marlborough, MA), and ammonium sulfate precipitation steps were carried out as described by Robins and Lindahl (26), except that the elution buffer for the first column contained 0.6 M KCl and the elution buffer for the second column contained 0.5 M NaCl. The active fractions in the second peak from the gel filtration column were pooled (63 mg of protein in a total volume of 54 ml), dialyzed against buffer A (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM dithiothreitol, 1 mM potassium phosphate, and 10% glycerol). The specific activity at this stage of purification was approximately 0.06 units/mg of protein, where one unit of enzyme is the amount required to incorporate 1 nmol of phosphate from ATP into micrococcal nuclease-treated DNA in 30 min at 37 °C (27). The pooled material was loaded onto a column (2.5 × 5.0 cm) of Bio-Gel HT hydroxyapatite (Bio-Rad) pre-equilibrated with buffer A. The column was washed with five volumes of buffer A before eluting bound protein with a 200-ml linear gradient of 50-500 mM potassium phosphate in buffer A collecting in 5-ml fractions. The active fractions, 28-33, were pooled and dialyzed against buffer B (10 mM potassium phosphate, pH 6.8, 4 mM 2-mercaptoethanol, and 10% glycerol) containing 50 mM KCl. The material was loaded onto a 1-ml HiTrap SP column (Amersham Pharmacia Biotech), washed with 10 column volumes of buffer B and eluted with a 30-ml linear gradient of 50-600 mM KCl in 30 1-ml fractions. A peak of kinase activity eluted at fractions 10-12. The contents of fraction 11 were dialyzed against buffer C (50 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, 1 mM potassium phosphate, and 10% glycerol) containing 50 mM NaCl, and loaded onto a Mono S PC 1.6/5 column attached to a SMART micropurification chromatography system (Amersham Pharmacia Biotech). Protein was eluted with a 2-ml linear salt gradient of 50-450 mM NaCl at a flow rate of 100 µl/min in 20 100-µl fractions. After assaying the fractions for DNA kinase activity, a small quantity of each fraction was examined by SDS-PAGE to determine which polypeptide correlated with activity. The remaining contents of the fraction with the peak of kinase activity (fraction 12) was further fractionated by gel electrophoresis and electroblotted onto polyvinylidene difluoride membrane.

Amino Acid Sequencing-- The electroblotted HeLa protein was stained with sulforhodamine B (0.05% w/v in 30% v/v aqueous methanol, 0.1% v/v acetic acid) using a rapid-staining protocol (28). The dried, stained protein was then digested in situ on the polyvinylidene difluoride membrane with trypsin (Roche Molecular Biochemicals, modified) for 18 h at 30 °C and the peptides extracted with 1:1 v/v formic acid/ethanol (29). Aliquots were sampled and directly analyzed by matrix-assisted laser desorption ionization (MALDI) time-of-flight mass spectrometry using a LaserMat 2000 mass spectrometer (Thermo Bioanalysis, UK) (30). Additional aliquots were quantitatively esterified using 1% v/v thionyl chloride in methanol and also analyzed by MALDI to provide acidic residue composition (31). Native and esterified peptide masses were then screened against the MOWSE peptide mass fingerprint data base (32). The remaining digested peptides (>90% of total digest) were then reacted with N-succinimidyl-2-morpholine acetate (SMA) in order to enhance b-ion abundance and facilitate sequence analysis by tandem mass spectrometry (33). Dried peptide fractions were treated with 7 µl of freshly prepared, ice-cold 1% w/v N-succinimidyl-2-morpholine acetate in 1.0 M HEPES (pH 7.8 with NaOH) containing 2% v/v acetonitrile. Following reaction for 20 min on ice, the reaction was terminated by the addition of 1 µl of heptafluorobutyric acid and diluted with an equal volume of water. The solution was then injected in three 5-µl aliquots onto a capillary reverse-phase column (300 µm x 15 cm) packed with POROS R2/H material (Perseptive Biosystems, MA) equilibrated with 2% v/v methanol, 0.05% v/v trifluoroacetic acid running at 3 µl/min. The adsorbed peptides were washed isocratically with 15% v/v methanol, 0.05% v/v trifluoroacetic acid for 30 min at 3 µl/min to elute the excess reagent and HEPES buffer. Derivatized peptides were eluted with a single step gradient to 75% v/v methanol, 0.1% v/v formic acid and collected in two 3-µl fractions. The derivatized peptides were then sequenced by low energy collision-activated dissociation using a Finnigan MAT TSQ7000 tandem triple quadrupole mass spectrometer and a Finnigan MAT LCQ ion-trap mass spectrometer, both instruments fitted with nanoelectrospray sources (34, 35). Collision-activated dissociation was typically performed with collisional offset voltages between -18 and -30 V.

Two tryptic peptides from previously purified calf thymus PNK (11) were sequenced by the Harvard Microchemistry Facility (Cambridge, MA) using either an ABI 477A protein sequencer (Applied Biosystems, Foster City, CA) or an HP G1000A (Hewlett Packard, Palo Alto, CA). Confirmation of sequence was obtained by MALDI time-of-flight mass spectrometry on a LaserMat 2000 mass spectrometer.

Isolation and Sequencing of Polynucleotide Kinase cDNA-- DNA sequences derived from the peptide sequences were used to screen the dbEST data base (NIH). A cDNA clone from infant brain (clone number 32798 inserted in lafmid BA) was identified and obtained from the I.M.A.G.E. Consortium. The cDNA insert (1548 bp) was fully sequenced, using an automated ABI Prism 377 DNA analysis system (Applied Biosystems), and confirmed the presence of the poly(A) tail, and a large open reading frame, but no clearly identifiable start codon. A 609-bp probe, prepared by digestion of clone 32798 with HindIII and PstI (New England Biolabs, Beverley, MA), was subsequently used to screen a lambda gt11 HeLa cell 5'-STRETCH PLUS cDNA library (CLONTECH, Palo Alto, CA) by a standard protocol (36). Ten positive clones were isolated, none of which contained a poly(A) tail. The largest insert (1.5 kilobase pairs) was amplified by PCR using the lambda  forward and reverse primers with Pfu DNA polymerase (Stratagene, La Jolla, CA), and then sequenced. Putative full-length cDNA was reconstituted as follows: (i) the PCR-amplified product was digested with SacI and shrimp alkaline phosphatase (Amersham Pharmacia Biotech), and the larger fragment (1.1 kilobase pairs) isolated by agarose gel electrophoresis, (ii) the DNA of clone 32798 was digested with SacI, (iii) the DNA molecules were ligated using phage T4 DNA ligase (Amersham Pharmacia Biotech), and (iv) the ligation product was digested with EcoRI.

Expression of PNK cDNA in E. coli-- The cDNA was amplified by PCR using Pfu DNA polymerase and primers with tails that provided cleavage sites for NdeI (5'-TTTGAATTCCCATATGGGCGAGGTGGAGCCCCCGGGC-3') and BamHI (5'-CGCGGATCCTCAGCCCTCGGAGAACTGGCAG-3') and then subcloned into the expression plasmid pET-16b (Novagen Inc., Madison, WI). The new plasmid (pPNK-His), which codes for a His-tagged derivative of PNK, was transfected into host E. coli bacterial strain BLR(DE3) (Novagen). The bacteria were grown at 37 °C to an OD600 of 0.6 in 100 ml of LB medium containing 50 µg/ml ampicillin and 12.5 µg/ml tetracycline. Zinc chloride was then added to the medium to a final concentration of 0.015 mM, and PNK expression was induced at 30 °C for 3 h by addition of 0.4 mM (final concentration) isopropyl-1-thio-beta -D-galactopyranoside (Sigma). After harvesting the cells by centrifugation at 5000 × g at 4 °C for 5 min, they were resuspended in 10 ml of extraction buffer (50 mM Tris-HCl, pH 7.5, 0.015 mM ZnCl2, 6 mM mercaptoethanol). Lysozyme was added to a final concentration of 100 µg/ml together with Triton X-100 (final concentration, 0.1%), and, after incubation at 30 °C for 15 min, the bacteria were disrupted by sonication. The soluble fraction was separated from the insoluble fraction by centrifugation at 12,000 × g for 15 min at 4 °C. The insoluble fraction was resuspended in 1 ml of extraction buffer.

Northern (RNA) Hybridization Analysis-- The 609-bp HindIII/PstI fragment used to screen the HeLa cDNA library was also used to probe a human multiple tissue Northern blot (CLONTECH) containing 2 µg (per lane) of polyadenylated RNA isolated from eight different human tissues. Hybridization was performed at 68 °C for 1 h under conditions described by the manufacturer. As a control for the amounts of mRNA in each lane, the membrane was reprobed with a sequence of beta -actin cDNA provided by CLONTECH.

Antibodies and Confocal Microscopy-- A synthetic peptide antigen was prepared commercially (SSPEQ, Quebec) from the first 17 amino acids of peptide sequence 1 (Table I) conjugated to a four-branch multiple antigenic peptide carrier. Rabbit polyclonal antibodies were raised by standard protocol (37).

The human malignant lung cell line A549 (ATCC no. CCL-185) was grown as a monolayer on glass microscope slides to 80% confluence. Following rinsing in PBS, the cells were fixed in 95% ethanol at -20 °C for 15 min. The slides were allowed to dry, and were incubated for 1 h at room temperature with 1% skim milk powder in PBS to minimize nonspecific binding of the immunoreagents. Following extensive PBS rinsing, the slides were incubated overnight at 4 °C in the rabbit polyclonal antiserum (diluted 1/30 in PBS), in a humidified atmosphere. The cells were then rinsed extensively with PBS, and rhodamine-conjugated goat anti-rabbit IgG (H+L, Cappel Laboratories, Durham, NC) was applied at a dilution of 1/30 in PBS for a 1-h incubation at 37 °C in a water-saturated atmosphere. The unbound fluorescent antibody was removed by extensive washing in PBS, and the slides were covered with coverslips for confocal microscopy using PBS/glycerol, 1:1 as a mounting medium. The instrumentation and the procedures for the confocal laser scanning microscopy have been described previously (38).

Fluorescence in Situ Chromosomal Hybridization-- Fluorescence in situ hybridization was performed as described previously (39). Human metaphase cells were prepared from phytohemagglutinin-stimulated peripheral blood lymphocytes. Biotin-labeled probes were prepared by nick translation using Bio-16-dUTP (Enzo Diagnostics, Farmingdale, NY). One PNK probe was clone 32798 (including the plasmid vector). A second probe, which provided a 440-bp sequence stretching from the 5'-untranslated region into the 5'-end of the translated sequence, was generated by PCR amplification of the HeLa cDNA clone using the lambda gt11 forward primer and a reverse primer, 5'-GTGGAGGCCATTGACCAAATA-3'. The two clones were labeled and co-hybridized to the chromosome preparations. Hybridization was detected with fluorescein-conjugated avidin (Vector Laboratories, Burlingame, CA), and chromosomes were identified by staining with 4,6-diamidino-2-phenylindole-dihydrochloride.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Partial Purification and Peptide Sequencing of Human PNK-- Fractions of a crude extract of HeLa cells that was passed down an AcA 34 Ultragel size exclusion column in the presence of 0.5 M NaCl were shown to contain DNA kinase activity (Fig. 1). Two peaks of activity were apparent, the first migrating with the bulk of the higher molecular weight protein, which may suggest that PNK is bound in a complex to other proteins, and the second eluting with proteins in the range of 40-100 kDa. Initial steps in the purification were carried out by conventional chromatography using gel filtration, hydroxyapatite, and cation exchange media. For the final step, the protein was applied on a SMART system precision column and eluted in 20 100-µl fractions with a 2-ml salt gradient (50-450 mM NaCl). The kinase assay revealed a peak of activity centering on fraction 12 (Fig. 2A). Correlation of the intensities of the protein bands in fractions 10-14 (Fig. 2B) with kinase activity strongly suggested that the ~60-kDa band (topmost of the three major bands in fraction 12, marked by an arrow) was responsible for the PNK activity. Accordingly, this band was chosen for amino acid sequencing.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   PNK activity eluting from a gel filtration column. Extracts from HeLa nuclei were applied in 0.5 M NaCl to an AcA 34 Ultragel size exclusion column, eluted with 0.5 M NaCl, collected in 6-ml fractions, and assayed as described under "Experimental Procedures." The void volume for the column was 180 ml. Solid lines indicate kinase activity (trichloroacetic acid-precipitable cpm) in the presence of micrococcal nuclease-treated DNA, while the dashed lines indicate kinase activity in the absence of added DNA.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 2.   Penultimate purification step of the HeLa PNK by elution from a Mono S PC 1.6/5 column. A, DNA kinase activity in each fraction. B, analysis by SDS-PAGE electrophoresis and silver staining of the protein content in the material loaded on the column, L, and in several of the eluted fractions (numbered above). Mobility of protein size markers (in kDa) is indicated on the left. The protein most clearly associated with kinase activity is marked by the arrow on the right.

Initial screening of the peptide mass fingerprint against the MOWSE protein sequence data base (approximately 210,000 entries) revealed no significant matches. Six tryptic peptides were then sequenced de novo by low energy collision-activated dissociation using both triple quadrupole and ion-trap mass spectrometry (peptides 3-8, Table I). The use of the SMA reagent permitted full sequences to be obtained for each peptide from a single collision spectrum. This was particularly important when sequencing by collision-activated dissociation using the ion-trap, where the SMA reagent typically yielded complete y-ion coverage. In addition, two peptide sequences (peptides 1 and 2, Table I) from our previously purified preparations of calf thymus PNK (11) were obtained by conventional amino acid sequencing.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Amino acid sequences obtained for tryptic peptides

Isolation and Sequencing of Human PNK cDNA-- Screening of the dbEST data base with peptides 1-6 revealed several human and murine cDNA clones with DNA sequences coding directly for the peptide sequences or with minor variations. Of these clones, clone 32798 (from the I.M.A.G.E. Consortium) contained the largest insert (1548 bp) of human DNA. Sequencing of clone 32798 (bases 208-1636, Fig. 3) showed the presence of a poly(A) tail, a consensus -AATAAA- polyadenylation signal (bases 1589-1594) and a large open reading frame, with a TGA stop codon at bases 1564-1566, containing in-frame sequences coding for peptides 2-5 and 8. The first valine in peptide 2 of the calf thymus enzyme is replaced by an isoleucine in human PNK. The insert was not long enough to account for the size of the protein determined by SDS-PAGE analysis, so a probe was prepared from the 5'-end of the insert of clone 32798 and used to screen a lambda gt11 HeLa cell cDNA library. Although 10 positives were obtained from this library, none contained a poly(A) tail. The largest insert (bases -90 to 1317; Fig. 3), however, extended the open reading frame to a putative start codon (bases 1-3) and included in-frame sequences coding for peptides 1, 6, and 7. Again there is a minor difference between the amino acid sequence between the bovine and human peptide 1. The 1100-bp sequences in common between clone 32798 and the HeLa clone are absolutely identical. The complete open reading frame codes for a 521-amino acid protein with a predicted molecular mass of 57,102 Da.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 3.   Nucleotide sequence and its encoded amino acid sequence for the cDNA of human PNK. Peptide domains of interest are boxed. Amino acid residues 170-176 are predicted to be associated with the phosphatase activity; residues 301-304 may be a nuclear localization signal; residues 372-380 constitute a P-loop ATP-binding domain; residues 402-464 may represent a DNA binding domain. Nucleotide sequences indicating the initiation and stop codons, the polyadenylation signal, and two 5'-UTR sequences with homology to complementary sequences in the 5'-UTR of DNase II are underlined.

Bacterial Expression of Human PNK-- After splicing together the full sequence shown in Fig. 3, the translated region was subcloned into an expression vector (pET-16b), to generate the plasmid pPNK-His, and expressed in a strain of E. coli as a His-tagged protein. After sonication of the bacteria to release protein, a strong band at ~60 kDa was observed in both the soluble and insoluble fractions (Fig. 4a). The 60-kDa band is the major protein in the insoluble fraction. Both the soluble and insoluble fractions showed clearly detectable levels of DNA kinase activity. (Data for the soluble fraction are shown in Fig. 4b. This is relatively straightforward because E. coli itself does not possess a DNA kinase activity that would interfere with the assay.)


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   Activities of recombinant PNK. a, comparison by SDS-PAGE of recombinant PNK (rPNK) and PNK isolated from HeLa cells. b, DNA kinase activity in the soluble fraction recovered from E. coli transfected with pET-16b and pPNK-His. The DNA phosphorylation assay was carried out with (+) and without (-) DNA as described under "Experimental Procedures" using 10 µg of cell extract. c, 3'-phosphatase activity in the insoluble fraction recovered from E. coli transfected with pET-16b and pPNK-His. The extracts (10 µg of total protein) were tested for their capacity to remove the 3'-phosphate from a 5'-32P-labeled 21-mer oligonucleotide (4 pmol) in 20 min as described previously (21).

3'-Phosphatase activity was measured by monitoring the removal of a 3'-phosphate group from a synthetic oligonucleotide (21). Fig. 4c shows the conversion of 5'-labeled p21p to p21 by protein from the bacteria harboring pPNK-His. In this case we made use of the protein in the inclusion bodies because nonspecific E. coli phosphatases were present in the soluble fraction.

Expression of PNK in Human Tissues-- Northern blot analysis of RNA isolated from a number of human tissues (Fig. 5) indicated a major transcript of approximately 2.3 kilobases, although in some tissues a second less abundant but considerably larger (7.5 kilobases) transcript was observed. There were also notable differences in the levels of mRNA expression in the tissues examined, in particular, pancreas and, to a lesser extent, heart appeared to have elevated levels of the message.


View larger version (86K):
[in this window]
[in a new window]
 
Fig. 5.   Confocal microscopy of PNK in human A549 cells. a, cells incubated with preimmune rabbit serum. There is faint cytoplasmic background labeling, but a lack of staining in the nucleus. b, cells incubated with rabbit polyclonal antibodies raised against a PNK-derived peptide (see "Experimental Procedures"). Pronounced nuclear staining is evident.

Cellular Localization of PNK-- Rabbit polyclonal antibodies were raised against a synthetic peptide composed of the first 17 amino acids in peptide 1 (Table I). These antibodies were used to visualize PNK in human A549 lung carcinoma cells by fluorescence confocal microscopy. The results, shown in Fig. 6, indicate that the protein accumulates in the cell nuclei.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 6.   PNK mRNA levels in human tissues. The polyadenylated RNA isolated from several tissues (CLONTECH) was probed with a 32P-labeled 609-bp (HindIII-PstI) fragment from clone 32798 (containing nucleotides 205-809 of the PNK sequence). A cDNA probe to beta -actin was used as a control for mRNA content.

Chromosomal Location of Human PNK-- To localize the PNK gene, we performed fluorescence in situ hybridization of biotin-labeled PNK cDNA probes to normal human metaphase chromosomes. Co-hybridization of two probes, EST clone 32798 and a 440-bp sequence stretching from the 5'-untranslated region into the 5'-end of the translated sequence, resulted in specific labeling only of chromosome 19 (Fig. 7). Specific labeling of 19q13.3-13.4 was observed on four (2 cells), three (9 cells), two (9 cells), or one (5 cells) chromatid(s) of the chromosome 19 homologues in 25 cells examined. Of 61 signals observed, 58 (95%) were located at 19q13.3-13.4. Of these, 11 (19%) signals were located at q13.3 and 47 (81%) signals were located at q13.4. Three single background signals were observed at other chromosomal sites (3p24.1, 4q21.2, and 1q43). We observed specific signal at 19q13.3-13.4 in additional experiments using the two cDNA probes hybridized individually. These results suggest that the PNK gene is localized to chromosome 19, band q13.4.


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 7.   In situ hybridization of biotin-labeled PNK probes to human metaphase cells from phytohemagglutinin-stimulated peripheral blood lymphocytes. The chromosome 19 homologues are identified with arrows; specific labeling was observed at 19q13.4. The inset shows partial karyotypes of two chromosome 19 homologues illustrating specific labeling at 19q13.4 (arrowheads). Images were obtained using a Zeiss Axiophot microscope coupled to a cooled charge-coupled device camera. Separate images of 4,6-diamidino-2-phenylindole-dihydrochloride-stained chromosomes and the hybridization signal were merged using image analysis software (NU200 and Image 1.57).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Gel electrophoresis of the partially purified DNA kinase activity from HeLa cells indicated that the human enzyme is a ~60-kDa polypeptide, and thus has a molecular mass similar to that of the proteins isolated from rat liver and calf thymus (11, 12, 20). The molecular mass of the 521-amino acid polypeptide encoded by the sequenced cDNA is 57,102 Da. The same computer program (ExPASy, Swiss Institute of Bioinformatics) also predicted a pI for the protein of 8.7, which is very close to the pI measured for the rat liver and calf thymus proteins of 8.6 and 8.5, respectively (10, 11). Expression of the protein in E. coli, and the demonstration of its kinase and phosphatase activities (Fig. 4), confirmed that we had indeed cloned the cDNA for human PNK.

The amino acid sequence (Fig. 3) indicates that this is a novel protein. However, as shown in Fig. 8, predicted proteins of Caenorhabditis elegans and Schizosaccharomyces pombe have ~30% similarity to human PNK. There are several large blocks of high similarity. Two in particular are probably associated with the two known activities of PNK. Other proteins possess these consensus sequences. The first, residues 372-380, conforms to the sequence pattern (A/G)-X4-G-K-(S/T) of the P-loop consensus sequence (40), which is an ATP/GTP binding domain found in many kinases, including nucleoside kinases such as adenylate and uridylate kinases (Table II). The second, residues 170-176, is a sequence found in several phosphatases (Table II), including carbohydrate-phosphate phosphatases like phosphoglycolate phosphatase and glycerol-3-phosphatase. This might be anticipated for a DNA phosphatase i.e. that dephosphorylates a deoxyribose phosphate. The homologous sequence in T4 PNK is part of a motif predicted by Jilani et al. (12) to be associated with the phosphatase activity of the T4 enzyme. Their conclusion was partly based on the observation that the first Asp in the homologous sequence of human phosphomannomutase 1 (Table II) has recently been shown to form an acyl-phosphate when incubated with its substrate (41). It is reasonable to suggest that the homologous Asp in human PNK may be a phosphate acceptor in the course of the enzyme's phosphatase activity. Both the P-loop and the phosphatase consensus sequences are found in phage T4 polynucleotide kinase and a putative PNK/RNA ligase from the nuclear polyhedrosis virus. There is, however, little other homology between the human kinase and the phage T4 PNK.


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 8.   Alignment of the sequence for human PNK with predicted sequences from C. elegans and S. pombe. Areas of high similarity are boxed. Dashed lines indicate that there is no gap in the sequence, and asterisks indicate the locations of additional amino acids.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Homologous peptide and DNA motifs

Two other potential functional regions were identified. The short motif, RKKK, residues 301-304, could be a nuclear localization signal belonging to a class of such signals consisting of four or more Arg or Lys residues or any combination of the two amino acids. That PNK has such a motif is consistent with the results of the confocal microscopy (Fig. 6), indicating the nuclear localization of the protein. The large domain between residues 402 and 464 (Fig. 3) is suggested by the program MacPattern to be a DNA binding domain. It is a relatively cysteine-rich sequence, and these amino acids may be involved in structuring such a domain.

Within the 5'-untranslated region (5'-UTR) of PNK are two closely spaced sequences (nucleotides -89 to -79 and -77 to -69) that have a high level of homology to sequences in the complementary strand of the 5'-UTR of DNase II (42) (Table II). This is of interest because DNase II, which has recently been implicated in apoptosis and cell differentiation (43-46), generates DNA strand breaks with 3'-phosphate and 5'-OH termini. If these nicks are repaired, it would presumably require the action of a polynucleotide kinase and, therefore, the regulation of the two enzymes may be coordinated.

The Northern blot (Fig. 5) suggested high expression of the protein in human pancreas. However, it must be borne in mind that this tissue is isolated from cadavers up to 3 h post-mortem. It is possible that the high level of PNK expression in pancreas reflects the high level of DNA degradation (presumably by nucleases such as DNase II) seen in post-mortem pancreatic tissue (47).

We have mapped the location of the gene for PNK to chromosome 19q13.4. Among the other genes that have been mapped to this locus are DNA polymerase delta , the apoptosis regulator gene BAX, protein kinase C, and several zinc finger proteins. The DNA repair enzymes, DNA ligase I and ERCC1, are located at 19q13.3 and DNase II at 19q13.2.

    ACKNOWLEDGEMENTS

We are grateful to Dr. Tomas Lindahl for generous support and encouragement, and we thank Dr. Deborah Barnes, Dr. Gernot Herrmann, Dr. Jean-Yves Masson, Dr. Guy Poirier, Dr. Vera Chlumecky, Dr. Michael Mitchell, and Dr. Rémy Aubin for their excellent advice and technical assistance. We also thank Dr. Dana Lasko for communicating results prior to publication.

    Note Added in Proof

The accompanying article by Jilani et al. (48) describes the independent identification and characterization of the same human DNA kinase, which they term PNKP.

    FOOTNOTES

* This work was supported by grants from the National Cancer Institute of Canada with funds from the Terry Fox Run, by a grant from the Medical Research Council of Canada (to M. W.) and by Public Health Service Grant CA40046 (to M. M. L.). The confocal microscope was purchased through funding of the Medical Research Council of Canada, the Alberta Heritage Foundation for Medical Research, and the Faculty of Medicine, University of Alberta.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF125807.

§§ Part of this work was carried out during a sabbatical stay at the ICRF Clare Hall Laboratories. To whom correspondence should be addressed: Experimental Oncology, Cross Cancer Inst., 11560 University Ave., Edmonton, Alberta T6G 1Z2, Canada. Tel.: 780-432-8438; Fax: 780-432-8428; E-mail: mweinfel@gpu.srv.ualberta.ca.

    ABBREVIATIONS

The abbreviations used are: PNK, polynucleotide kinase or polydeoxyribonucleotide kinase; p21p, a 21-mer oligonucleotide phosphorylated at the 3'- and 5'-termini; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; MALDI, matrix-assisted laser desorption ionization; SMA, N-succinimidyl-2-morpholine acetate; bp, base pair(s); UTR, untranslated region; PCR, polymerase chain reaction.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Bernardi, G. (1968) Adv. Enzymol. 31, 1-49
2. Coquerelle, T., Bopp, A., Kessler, B., and Hagen, U. (1973) Int. J. Radiat. Biol. 24, 397-404
3. Lennartz, M., Coquerelle, T., and Hagen, U. (1975) Int. J. Radiat. Biol. 27, 577-587
4. Henner, W. D., Rodriguez, L. O., Hecht, S. M., and Haseltine, W. A. (1983) J. Biol. Chem. 258, 711-713[Abstract/Free Full Text]
5. Midgley, C. A., and Murray, N. E. (1985) EMBO J. 4, 2695-2703[Medline] [Order article via Infotrieve]
6. Amitsur, M., Levitz, R., and Kaufmann, G. (1987) EMBO J. 6, 2499-2503[Medline] [Order article via Infotrieve]
7. Kleppe, K., and Lillehaug, J. R. (1979) Adv. Enzymol. 48, 245-275
8. Pheiffer, B. H., and Zimmerman, S. B. (1982) Biochem. Biophys. Res. Commun. 109, 1297-1302[Medline] [Order article via Infotrieve]
9. Habraken, Y., and Verly, W. G. (1983) FEBS Lett. 160, 46-50[CrossRef][Medline] [Order article via Infotrieve]
10. Habraken, Y., and Verly, W. G. (1988) Eur. J. Biochem. 171, 59-66[Medline] [Order article via Infotrieve]
11. Karimi-Busheri, F., and Weinfeld, M. (1997) J. Cell. Biochem. 64, 258-272[CrossRef][Medline] [Order article via Infotrieve]
12. Jilani, A., Slack, C., Matheos, D., Zannis-Hadjopoulos, M., and Lasko, D. D. (1999) J. Cell. Biochem. 73, 188-203[CrossRef][Medline] [Order article via Infotrieve]
13. Ichimura, M., and Tsukada, K. (1971) J. Biochem. (Tokyo) 69, 823-828[Abstract/Free Full Text]
14. Teraoka, H., Mizuta, K., Sato, F., Shimoyachi, M., and Tsukada, K. (1975) Eur. J. Biochem. 58, 297-302[Medline] [Order article via Infotrieve]
15. Levin, C., and Zimmerman, S. B. (1976) J. Biol. Chem. 251, 1767-1774[Abstract/Free Full Text]
16. Austin, G. E., Sirakoff, D., Roop, B., and Moyer, G. H. (1978) Biochim. Biophys. Acta 522, 412-422[Medline] [Order article via Infotrieve]
17. Tamura, S., Teraoka, H., and Tsukada, K. (1981) Eur. J. Biochem. 115, 449-453[Medline] [Order article via Infotrieve]
18. Bosdal, T., and Lillehaug, J. R. (1985) Biochim. Biophys. Acta 840, 280-286[Medline] [Order article via Infotrieve]
19. Prinos, P., Slack, C., and Lasko, D. D. (1995) J. Cell. Biochem. 58, 115-131[CrossRef][Medline] [Order article via Infotrieve]
20. Ohmura, Y., Uchida, T., Teraoka, H., and Tsukada, K. (1987) Eur. J. Biochem. 162, 15-18[Medline] [Order article via Infotrieve]
21. Karimi-Busheri, F., Lee, J., Tomkinson, A. E., and Weinfeld, M. (1998) Nucleic Acids Res. 26, 4395-4400[Abstract/Free Full Text]
22. Yang, S.-W., Burgin Jr, A. B., Huizenga, B. N., Robertson, C. A., Yao, K. C., and Nash, H. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11534-11539[Abstract/Free Full Text]
23. Pohjanpelto, P., and Hölttä, E. (1996) EMBO J. 15, 1193-1200[Medline] [Order article via Infotrieve]
24. Richardson, C. C. (1965) Proc. Natl. Acad. Sci. U. S. A. 54, 158-165[Free Full Text]
25. Masutani, C., Sugasawa, K., Yanagisawa, J., Sonoyama, T., Ui, M., Enomoto, T., Takio, K., Tanaka, K., van der Spek, P. J., Bootsma, D., Hoeijmakers, J. H. J., and Hanaoka, F. (1994) EMBO J. 13, 1831-1843[Medline] [Order article via Infotrieve]
26. Robins, P., and Lindahl, T. (1996) J. Biol. Chem. 271, 24257-24261[Abstract/Free Full Text]
27. Richardson, C. C. (1971) in Procedures in Nucleic Acid Research (Cantoni, G. L. , and Davies, D. R., eds), Vol. 2 , pp. 815-828, Harper and Row, New York
28. Coull, J. M., and Pappin, D. J. C. (1990) J. Protein Chem. 9, 259-260
29. Sutton, C. W., Pemberton, K. S., Cottrell, J. S., Corbett, J. M., Wheeler, C. H., Dunn, M. J., and Pappin, D. J. C. (1995) Electrophoresis 16, 308-316[CrossRef][Medline] [Order article via Infotrieve]
30. Mock, K. K., Sutton, C. W., and Cottrell, J. S. (1992) Rapid Commun. Mass Spectrom. 6, 233-238[CrossRef][Medline] [Order article via Infotrieve]
31. Pappin, D. J. C., Rahman, D., Hansen, H. F., Bartlet-Jones, M., Jeffery, W. A., and Bleasby, A. J. (1996) in Mass Spectrometry in the Biological Sciences (Burlingame, A. L. , and Carr, S. A., eds) , pp. 135-150, Humana Press, Totowa, NJ
32. Pappin, D. J. C., Hojrup, P., and Bleasby, A. J. (1993) Curr. Biol. 3, 327-332[CrossRef][Medline] [Order article via Infotrieve]
33. Sherman, N. E., Yates, N. A., Shabanowitz, J., Hunt, D. F., Jeffery, W. A., Bartlet-Jones, M., and Pappin, D. J. C. (1995) Proceedings of the 43rd ASMS Conference on Mass Spectrometry and Allied Topics, May 21-26, 1995, Atlanta, GA
34. Hunt, D. F., Yates, J. R., Shabanowitz, J., Winston, S., and Hauer, C. R. (1986) Proc. Natl. Acad. Sci. U. S. A. 84, 6233-6237
35. Wilm, M., and Mann, M. (1996) Anal. Chem. 68, 1-8[Medline] [Order article via Infotrieve]
36. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
37. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
38. Miller, G. G., Brown, K., Moore, R. B., Diwu, Z. J., Liu, J., Huang, L., Lown, J. W., Begg, D. A., Chlumecky, V., Tulip, J., and McPhee, M. S. (1995) Photochem. Photobiol. 61, 632-638[Medline] [Order article via Infotrieve]
39. Rowley, J. D., Diaz, M. O., Espinosa, R., Patel, Y. D., van Melle, E., Ziemin, S., Taillon-Miller, P., Lichter, P., Evans, G. A., Kersey, J. D., Ward, D. C., Domer, P. H., and Le Beau, M. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9358-9362[Abstract/Free Full Text]
40. Saraste, M., Sibbald, P. R., and Wittinghofer, A. (1990) Trends Biochem. Sci. 15, 430-434[CrossRef][Medline] [Order article via Infotrieve]
41. Collet, J-F., Strooban, V., Pirard, M., Delpierre, G., and Van Schaftingen, E. (1998) J. Biol. Chem. 273, 14107-14112[Abstract/Free Full Text]
42. Yasuda, T., Takeshita, H., Iida, R., Nakajima, T., Hosomi, O., Nakashima, Y., and Kishi, K. (1998) J. Biol. Chem. 273, 2610-2616[Abstract/Free Full Text]
43. Barry, M. A., Reynolds, J. E., and Eastman, A. (1993) Cancer Res. 53 (suppl.), 2349-2357[Abstract/Free Full Text]
44. Barry, M. A., and Eastman, A. (1993) Arch. Bioch. Biophys. 300, 440-450[CrossRef][Medline] [Order article via Infotrieve]
45. Torriglia, A., Chaudun, E., Chany-Fournier, F., Jeanny, J. C., Courtois, Y., and Counis, M. F. (1995) J. Biol. Chem. 270, 28579-28585[Abstract/Free Full Text]
46. Torriglia, A., Perani, P., Brossas, J. Y., Chaudun, E., Treton, J., Courtois, Y., and Counis, M. F. (1998) Mol. Cell. Biol. 18, 3612-3619[Abstract/Free Full Text]
47. Yokoi, T., and Sagisaka, K. (1990) Forensic Sci. Int. 45, 39-46[CrossRef][Medline] [Order article via Infotrieve]
48. Jilani, A., Ramotar, D., Slack, C., Ong, C., Yang, X., Scherer, S. W., and Lasko, D. D. (1999) J. Biol. Chem. 274, 24176-24186[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. S. Mani, M. Fanta, F. Karimi-Busheri, E. Silver, C. A. Virgen, K. W. Caldecott, C. E. Cass, and M. Weinfeld
XRCC1 Stimulates Polynucleotide Kinase by Enhancing Its Damage Discrimination and Displacement from DNA Repair Intermediates
J. Biol. Chem., September 21, 2007; 282(38): 28004 - 28013.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Karimi-Busheri, A. Rasouli-Nia, J. Allalunis-Turner, and M. Weinfeld
Human Polynucleotide Kinase Participates in Repair of DNA Double-Strand Breaks by Nonhomologous End Joining but not Homologous Recombination
Cancer Res., July 15, 2007; 67(14): 6619 - 6625.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Zheng, H. Dai, J. Qiu, Q. Huang, and B. Shen
Disruption of the FEN-1/PCNA Interaction Results in DNA Replication Defects, Pulmonary Hypoplasia, Pancytopenia, and Newborn Lethality in Mice
Mol. Cell. Biol., April 15, 2007; 27(8): 3176 - 3186.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
C. J. Dobson and S. L. Allinson
The phosphatase activity of mammalian polynucleotide kinase takes precedence over its kinase activity in repair of single strand breaks.
Nucleic Acids Res., January 1, 2006; 34(8): 2230 - 2237.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
Z. Tang, K. Wang, W. Tan, C. Ma, J. Li, L. Liu, Q. Guo, and X. Meng
Real-time investigation of nucleic acids phosphorylation process using molecular beacons
Nucleic Acids Res., June 16, 2005; 33(11): e97 - e97.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Blondal, S. Hjorleifsdottir, A. Aevarsson, O. H. Fridjonsson, S. Skirnisdottir, J. O. Wheat, A. G. Hermannsdottir, G. O. Hreggvidsson, A. V. Smith, and J. K. Kristjansson
Characterization of a 5'-Polynucleotide Kinase/3'-Phosphatase from Bacteriophage RM378
J. Biol. Chem., February 18, 2005; 280(7): 5188 - 5194.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
T. Zhou, J. W. Lee, H. Tatavarthi, J. R. Lupski, K. Valerie, and L. F. Povirk
Deficiency in 3'-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1)
Nucleic Acids Res., January 12, 2005; 33(1): 289 - 297.
[Abstract] [Full Text] [PDF]